SCHEMBL22774166

SCHEMBL22774166

Cc1cc2nc(Br)ccc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.41
CYP2A6 P11509 1/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 2/20 0.41
AXL P30530 1/20 0.39
MAPT P10636 6/20 0.35
ALDH1A1 P00352 5/20 0.35
KDM4E B2RXH2 5/20 0.35
GAA P10253 3/20 0.35
RXFP1 Q9HBX9 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ABL1 P00519 1/20 0.35
RET P07949 1/20 0.35
KDR P35968 1/20 0.35
CDK7 P50613 1/20 0.35
CDK5 Q00535 1/20 0.35
PRKAA1 Q13131 1/20 0.35
AURKB Q96GD4 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
CYP1A2 P05177 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26262615 0.79 LMNA (0.34) LMNAALDH1A1KDM4ECLK4HSD17B10
SCHEMBL4904552 0.79 KEAP1 (0.44) KEAP1CYP2A6LMNAHPGDAXL
SCHEMBL29377868 0.77 AXL (0.49) KEAP1CYP2A6HPGDAXLMAPT
SCHEMBL9959317 0.77 AXL (0.49) KEAP1CYP2A6HPGDAXLMAPT
SCHEMBL4008095 0.76 KEAP1 (0.41) KEAP1CYP2A6LMNAHPGDAXL
SCHEMBL22774172 0.76 KDM4E (0.33) KEAP1LMNAMAPTKDM4EKDR
SCHEMBL15431204 0.76 CYP2A6 (0.50) KEAP1CYP2A6AXLMAPTALDH1A1
SCHEMBL19212554 0.76 KEAP1 (0.41) KEAP1CYP2A6LMNAHPGDAXL
SCHEMBL29594892 0.76 KEAP1 (0.41) KEAP1CYP2A6LMNAHPGDAXL
SCHEMBL22790140 0.76 DDAH1 (0.37) LMNAMAPTALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
US-20220306623-A1 PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-09-29 US disclosed
EP-3983409-A1 PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2022-04-20 EP disclosed
CN-114008044-A Pyridyl or pyrimidinyl MTOR kinase inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2022-02-01 CN disclosed
WO-2020249652-A1 PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-12-17 WO disclosed
WO-2020249652-A1 PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF NSD3, PML, NSD1 KEAP1 1700/4885CYP2A6 2579/4885LMNA 1896/4885
US-20220306623-A1 PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS MTOR, RICTOR, RPTOR KEAP1 963/4885CYP2A6 2338/4885LMNA 3759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.